Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lipoic acid (alpha-lipoic acid, ALA) has been investigated for its potential neuroprotective and antioxidant effects in glaucoma. Glaucoma is characterized by progressive optic nerve damage, often associated with oxidative stress and apoptosis of retinal ganglion cells. Some scientific studies, primarily in animal models and a few small human trials, have explored the effects of lipoic acid supplementation in this context.

Experimental research suggests that lipoic acid can reduce oxidative damage in ocular tissues and may help to preserve retinal ganglion cells under conditions simulating glaucoma. For example, animal studies have shown that ALA can protect against retinal damage induced by elevated intraocular pressure, likely due to its ability to scavenge free radicals and support mitochondrial function. A few small clinical studies have reported improvement or stabilization of visual function parameters in glaucoma patients taking lipoic acid supplements, but these studies are limited in size and methodology.

There is not yet robust, large-scale clinical evidence to fully support the routine use of lipoic acid for glaucoma. Most recommendations for its use are based on its general antioxidant properties and preliminary research rather than conclusive clinical trials. Therefore, while there is some scientific rationale and early evidence, the overall strength of the evidence is weak (rated 2/5), and lipoic acid should not be considered a primary or standalone therapy for glaucoma at this time.

More about Lipoic Acid
More about Glaucoma

Other ingredients used for Glaucoma

Other health conditions supported by Lipoic Acid

Products containing Lipoic Acid